Incyte
INCY
$51.74
Share price
0.17%
Change (1 day)
-31.24%
Change (1 year)
Categories
Operating Margin for Incyte (INCY)
Operating Margin as of April 2024 (TTM): 15.90%
According to Incyte's latest financial reports and stock price the company's current Operating Margin is 15.90%. At the end of 2022 the company had an Operating Margin of 15.67%.
Operating Margin history for Incyte from 2001 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | 15.67% | -18.27% |
| 2021 | 19.17% | -322.18% |
| 2020 | -8.63% | -138.11% |
| 2019 | 22.64% | 264.42% |
| 2018 | 6.21% | -131.25% |
| 2017 | -19.88% | -250.4% |
| 2016 | 13.22% | 87.41% |
| 2015 | 7.05% | -2198.53% |
| 2014 | -0.34% | -97.3% |
| 2013 | -12.45% | -2034.52% |
| 2012 | 0.64% | -100.42% |
| 2011 | -151.59% | -1932.98% |
| 2010 | 8.27% | -100.55% |
| 2009 | -1,508.56% | -62.88% |
| 2008 | -4,064.53% | 1541.45% |
| 2007 | -247.62% | -10.95% |
| 2006 | -278.06% | -78.35% |
| 2005 | -1,284.53% | 22.07% |
| 2004 | -1,052.26% | 329.61% |
| 2003 | -244.93% | 154.2% |
| 2002 | -96.35% | 226.54% |
| 2001 | -29.51% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 17.27% | 8.62% | 🇨🇭 Switzerland |
 Pfizer PFE | 34.61% | 117.67% | 🇺🇸 USA |
 Eli Lilly LLY | 24.66% | 55.09% | 🇺🇸 USA |
 Amgen AMGN | 34.59% | 117.55% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 17.06% | 7.30% | 🇺🇸 USA |
 Geron GERN | -23,808.90% | -149,841.51% | 🇺🇸 USA |
 CTI BioPharma
CTIC | -172.37% | -1,184.09% | 🇺🇸 USA |
 AVEO Oncology
AVEO | -30.78% | -293.58% | 🇺🇸 USA |
 Ardelyx ARDX | -104.48% | -757.11% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.